Search

Search Constraints

You searched for: Author/Creator Porter, Danielle

Search Results

2. 537STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96. (December 2014)

3. Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis. Issue 9 (September 2019)

5. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. (September 2021)

7. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. (January 2016)

8. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Issue 12 (December 2016)

9. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. (September 2017)

10. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Issue 5 (May 2017)